IL259512B2 - Combination for the effective treatment of metastatic cancer in patients - Google Patents
Combination for the effective treatment of metastatic cancer in patientsInfo
- Publication number
- IL259512B2 IL259512B2 IL259512A IL25951218A IL259512B2 IL 259512 B2 IL259512 B2 IL 259512B2 IL 259512 A IL259512 A IL 259512A IL 25951218 A IL25951218 A IL 25951218A IL 259512 B2 IL259512 B2 IL 259512B2
- Authority
- IL
- Israel
- Prior art keywords
- dose
- hydroxocobalamin
- combination
- nitrosourea
- chloroethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263880P | 2015-12-07 | 2015-12-07 | |
| PCT/US2016/065079 WO2017100162A1 (en) | 2015-12-07 | 2016-12-06 | Combination for the effective treatment of metastatic cancer in patients |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL259512A IL259512A (en) | 2018-07-31 |
| IL259512B1 IL259512B1 (en) | 2023-11-01 |
| IL259512B2 true IL259512B2 (en) | 2024-03-01 |
Family
ID=57708742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL259512A IL259512B2 (en) | 2015-12-07 | 2016-12-06 | Combination for the effective treatment of metastatic cancer in patients |
| IL290251A IL290251B2 (en) | 2015-12-07 | 2016-12-06 | Combination for the effective treatment of metastatic cancer in patients |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL290251A IL290251B2 (en) | 2015-12-07 | 2016-12-06 | Combination for the effective treatment of metastatic cancer in patients |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11154520B2 (https=) |
| EP (1) | EP3386546B1 (https=) |
| JP (3) | JP6831853B2 (https=) |
| KR (1) | KR20180086257A (https=) |
| AU (2) | AU2016367112B2 (https=) |
| CA (1) | CA3044959C (https=) |
| DK (1) | DK3386546T3 (https=) |
| ES (1) | ES2994931T3 (https=) |
| FI (1) | FI3386546T3 (https=) |
| HU (1) | HUE069668T2 (https=) |
| IL (2) | IL259512B2 (https=) |
| PL (1) | PL3386546T3 (https=) |
| PT (1) | PT3386546T (https=) |
| WO (1) | WO2017100162A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150265641A1 (en) | 2012-10-22 | 2015-09-24 | Arnold Glazier | Methods for the Effective Treatment of Metastatic Cancer |
| US11298338B2 (en) * | 2016-06-06 | 2022-04-12 | University Of Iowa Research Foundation | Compositions and methods for cancer therapy |
| EP3840744B1 (en) | 2018-08-21 | 2025-06-04 | Board of Regents, The University of Texas System | Compositions and methods for the treatment of cancer cells by induction of cytotoxic oxidative stress |
| CN114904011B (zh) * | 2021-07-06 | 2023-10-13 | 中国科学院上海硅酸盐研究所 | 非铁基谷胱甘肽消耗协同活性氧物种增强复合材料及其制备方法和应用 |
| JP2024528725A (ja) * | 2021-07-29 | 2024-07-30 | ランタン ファルマ インコーポレイテッド | Ｐａｒｐ阻害剤及びアシルフルベンの併用によるがんの治療 |
| CN116407557A (zh) * | 2023-05-29 | 2023-07-11 | 四川大学华西医院 | 一种防治出血性脑卒中的药物组合物及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150265641A1 (en) * | 2012-10-22 | 2015-09-24 | Arnold Glazier | Methods for the Effective Treatment of Metastatic Cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1305873C (en) * | 1987-05-26 | 1992-08-04 | Howel Gwynne Giles | Method and means for detecting alcohol levels in humans |
| US5639787A (en) | 1995-02-28 | 1997-06-17 | The Center For The Improvement Of Human Functioning Int'l, Inc. | Therapeutic method for the treatment of cancer |
| JP2003501488A (ja) | 1999-06-11 | 2003-01-14 | ネオルックス コーポレイション | 骨髄抑制のための高投与量放射性核種錯体 |
| JP5102928B2 (ja) * | 2000-06-30 | 2012-12-19 | イーライ リリー アンド カンパニー | 新規な葉酸代謝拮抗薬の組み合わせ療法 |
| AU2003221517B2 (en) | 2002-03-22 | 2010-02-18 | Christian Straka | Cytocapacity test |
| EP1565193B1 (en) | 2002-11-06 | 2013-04-24 | Dana-Farber Cancer Institute, Inc. | Compositions for treating cancer using proteasome inhibitor PS-341 |
| US20090123447A1 (en) * | 2007-11-14 | 2009-05-14 | The Regents Of The University Of California | Compositions and methods to inhibit rna viral reproduction |
| WO2011011317A1 (en) * | 2009-07-20 | 2011-01-27 | Summa Health System | Vitamin c and vitamin k, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant |
-
2016
- 2016-12-06 AU AU2016367112A patent/AU2016367112B2/en active Active
- 2016-12-06 WO PCT/US2016/065079 patent/WO2017100162A1/en not_active Ceased
- 2016-12-06 IL IL259512A patent/IL259512B2/en unknown
- 2016-12-06 PT PT168204048T patent/PT3386546T/pt unknown
- 2016-12-06 FI FIEP16820404.8T patent/FI3386546T3/fi active
- 2016-12-06 US US15/778,796 patent/US11154520B2/en active Active
- 2016-12-06 IL IL290251A patent/IL290251B2/en unknown
- 2016-12-06 EP EP16820404.8A patent/EP3386546B1/en active Active
- 2016-12-06 JP JP2018549135A patent/JP6831853B2/ja active Active
- 2016-12-06 CA CA3044959A patent/CA3044959C/en active Active
- 2016-12-06 ES ES16820404T patent/ES2994931T3/es active Active
- 2016-12-06 HU HUE16820404A patent/HUE069668T2/hu unknown
- 2016-12-06 DK DK16820404.8T patent/DK3386546T3/da active
- 2016-12-06 PL PL16820404.8T patent/PL3386546T3/pl unknown
- 2016-12-06 KR KR1020187019041A patent/KR20180086257A/ko not_active Ceased
-
2021
- 2021-01-29 JP JP2021013001A patent/JP7144554B2/ja active Active
- 2021-10-13 US US17/500,169 patent/US20220096405A1/en not_active Abandoned
-
2022
- 2022-01-11 AU AU2022200131A patent/AU2022200131A1/en not_active Abandoned
- 2022-09-15 JP JP2022147352A patent/JP2022171816A/ja active Pending
-
2024
- 2024-01-09 US US18/408,066 patent/US20240216308A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150265641A1 (en) * | 2012-10-22 | 2015-09-24 | Arnold Glazier | Methods for the Effective Treatment of Metastatic Cancer |
Non-Patent Citations (4)
| Title |
|---|
| AKATOV, V.S. ET AL.,, OXIDATIVE STRESS IN HEP-2 HUMAN LARYNGEALCARCINOMA CELLS INDUCED BY COMBINATION OF VITAMINS B12B AND C,, 31 December 2003 (2003-12-31) * |
| POYDOCK M E ET AL,, GROWTH-INHIBITING EFFECT OF HYDROXOCOBALAMIN AND L-ASCORBIC ACID ON TWO SOLID TUMORS IN MICE, 31 December 1984 (1984-12-31) * |
| POYDOCK M E ET AL,, INFLUENCE OF VITAMINS C AND B12 ON THE SURVIVAL RATE OF MICE BEARING ASCITES TUMOR, 1 January 1982 (1982-01-01) * |
| POYDOCK M E,, EFFECT OF COMBINED ASCORBIC ACID AND B-12 ON SURVIVAL OF MICE WITH IMPLANTED EHRLICH CARCINOMA AND L1210 LEUKEMIA, 1 December 1991 (1991-12-01) * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7144554B2 (ja) | 2022-09-29 |
| PL3386546T3 (pl) | 2025-01-27 |
| CA3044959C (en) | 2024-01-09 |
| IL290251A (en) | 2022-04-01 |
| US20240216308A1 (en) | 2024-07-04 |
| DK3386546T3 (en) | 2024-11-25 |
| JP2021073262A (ja) | 2021-05-13 |
| US20180338935A1 (en) | 2018-11-29 |
| JP2022171816A (ja) | 2022-11-11 |
| IL290251B1 (en) | 2024-03-01 |
| IL259512A (en) | 2018-07-31 |
| CA3044959A1 (en) | 2017-06-15 |
| KR20180086257A (ko) | 2018-07-30 |
| AU2022200131A1 (en) | 2022-02-10 |
| US11154520B2 (en) | 2021-10-26 |
| WO2017100162A1 (en) | 2017-06-15 |
| IL259512B1 (en) | 2023-11-01 |
| JP2019501962A (ja) | 2019-01-24 |
| AU2016367112A1 (en) | 2018-07-12 |
| IL290251B2 (en) | 2024-07-01 |
| FI3386546T3 (fi) | 2024-12-05 |
| US20220096405A1 (en) | 2022-03-31 |
| AU2016367112B2 (en) | 2022-01-13 |
| ES2994931T3 (en) | 2025-02-04 |
| PT3386546T (pt) | 2024-12-09 |
| EP3386546B1 (en) | 2024-09-04 |
| EP3386546A1 (en) | 2018-10-17 |
| JP6831853B2 (ja) | 2021-02-17 |
| HUE069668T2 (hu) | 2025-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259512B2 (en) | Combination for the effective treatment of metastatic cancer in patients | |
| Lozada-Delgado et al. | RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials | |
| ES2661216T3 (es) | Método combinado para tratar el cáncer o un estado precanceroso | |
| RU2017126610A (ru) | Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47 | |
| WO2016210376A3 (en) | Therapeutic peptides and methods of use thereof | |
| MX339142B (es) | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. | |
| MX2022011334A (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. | |
| WO2012159085A3 (en) | Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells | |
| EP4124346A3 (en) | Compositions and methods for treating diseases | |
| PH12019502660A1 (en) | RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| JP2019526559A5 (https=) | ||
| WO2014160216A3 (en) | Dual targeting anticancer agents | |
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| JP2016515586A5 (https=) | ||
| JP2014512391A5 (https=) | ||
| ZA202207211B (en) | Peptide docking vehicle for targeted nucleic acid delivery | |
| MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. | |
| BR112022019914A2 (pt) | Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres | |
| PH12021552977A1 (en) | Methods of treating urinary system cancers | |
| AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas | |
| RU2015139515A (ru) | Комбинированное лечение | |
| JP2015524467A5 (https=) | ||
| JP2009517356A5 (https=) | ||
| WO2016018454A3 (en) | Compositions and methods employing bcl2 and bcl2 family members |